Fourth Amendment to Research and Development AgreementResearch and Development Agreement • November 7th, 2019 • Ziopharm Oncology Inc • Pharmaceutical preparations • New York
This Fourth Amendment to Research and Development Agreement (this “Fourth Amendment”) is made as of March __, 2019 and effective on October 5, 2018 (the “Fourth Amendment Effective Date”), by and among THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (“UTMDACC”), a member institution of THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), ZIOPHARM ONCOLOGY, INC., a Delaware corporation (“ZIOPHARM”), and PRECIGEN, INC. (“PRECIGEN”) (as assignee of INTREXON CORPORATION (“INTREXON”)).
